- Home
- ASRT vs NRXP Comparison
ASRT vs NRXP Comparison
Compare ASRT & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASRT | NRXP |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.0M | 54.2M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | ASRT | NRXP |
|---|---|---|
| Price | $11.39 | $1.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $35.00 | $31.50 |
| AVG Volume (30 Days) | 23.2K | ★ 487.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $124,961,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.42 | $847.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $1.58 |
| 52 Week High | $12.95 | $3.84 |
Technical Indicators
Market Signals| Indicator | ASRT | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 48.91 | 45.77 |
| Support Level | $11.05 | $1.65 |
| Resistance Level | $12.45 | $1.99 |
| Average True Range (ATR) | 0.44 | 0.09 |
| MACD | -0.17 | 0.01 |
| Stochastic Oscillator | 30.06 | 42.83 |
Price Performance
Historical ComparisonAbout ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.